Antibody · 방광·요로상피

21개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved21 programs
AntibodyCurated CoreFDARocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyCurated CorestaleAstraZenecaPhase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+4
Trials 195Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 65Status Active
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#Popular#monoclonal-antibody+1
Trials 61Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 35Status Active
AntibodyLimited DatastaleDiwakar DavarPhase 2

Domvanalimab (Domvanalimab)

Melanoma · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#Antibody#Phase2#monoclonal-antibody#Melanoma+1
Trials 22Status Recruiting
AntibodyLimited DatastaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 16Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Upper Tract Urothelial Carcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#UpperTractUrothelialCarcinoma+1
Trials 12Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated favezelimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#UrothelialNeoplasms+1
Trials 6Status Recruiting
AntibodyLimited DatastaleThe Affiliated Nanjing Drum Tow…Phase 2

Triplizumab (Triplizumab)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#monoclonal-antibody#The
Trials 6Status Active
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated vibostolimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#UrothelialNeoplasms+1
Trials 2Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, AMVAC + Nivolumab)

Muscle-Invasive Bladder Carcinoma · Muscle-Invasive Bladder Carcinoma

#Muscle-InvasiveBladderCarcinoma#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#UrothelialCarcinomaBladder+1
Trials 1Status Active
AntibodyLimited DatastaleWeill Medical College of Cornel…Phase 1

Naptumomab Estafenatox (Naptumomab Estafenatox)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#Weill
Trials 1Status Discontinued
AntibodyLimited DatastaleSwiss Cancer InstitutePhase 2

durvalumab (Imfinzi, Neoadjuvant and adjuvant durvalumab)

Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#Antibody#Phase2#monoclonal-antibody#Swiss
Trials 1Status Active
AntibodyLimited DatastaleSeoul National University Hospi…Preclinical

atezolizumab (Tecentriq, Neoadjuvant atezolizumab)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Preclinical#monoclonal-antibody#Seoul
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#monoclonal-antibody#Changhai
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleMedPacto, Inc.Phase 2

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent

#UrothelialCarcinomaRecurrent#Antibody#Phase2#monoclonal-antibody#AdvancedUrothelialCarcinoma+1
Trials 1Status Discontinued

1 / 2 pages

← PreviousNext →